Nexalis Therapeutics Completes Phase 1 Panic Drug Trial With Zero Safety Events
Nexalis Therapeutics completes dosing in Phase 1 IRX-616a panic disorder trial
Nexalis Therapeutics (ASX: NX1) has completed dosing of all patients in its Phase 1 clinical trial of IRX-616a, its inhaled cannabidiol (CBD) formulation targeting acute panic and anxiety episodes. The Last Patient Last Dose (LPLD) milestone marks the conclusion of the dosing phase of the first-in-human study, a randomised, double-blind, placebo-controlled trial conducted at CMAX Adelaide across three sequential dose cohorts in healthy volunteers.
Critically, zero Serious Adverse Events (SAEs) were reported across the entire study. The company has now initiated Phase 2 planning and regulatory preparation activities, signalling forward momentum with no gap between phases.
CEO Darryl Davies
“Completing dosing in our Phase 1 IRX-616a study is a significant achievement for Nexalis and an important step in advancing our rapid-onset therapeutic platform. We are particularly encouraged by the absence of any SAEs observed during the study and delighted with the early insights emerging from the pharmacokinetic profile of IRX-616a. These outcomes continue to strengthen our confidence in the program as we commence preparations for Phase 2 development.”
When big ASX news breaks, our subscribers know first
Why IRX-616a targets a clear gap in panic disorder treatment
Panic Disorder is a mental health condition characterised by recurring, unexpected panic attacks, which are sudden episodes of intense fear accompanied by physical symptoms such as a racing heart, shortness of breath, and dizziness. Current treatment options primarily consist of daily oral medications, such as antidepressants or benzodiazepines, which are not designed to address the acute, rapid-onset nature of a panic episode as it occurs.
Critically, as stated in the announcement, there are currently no FDA-approved drugs delivered via inhalation designed to treat Panic Disorder. This represents a meaningful gap in the treatment landscape.
Inhalation as a delivery route is strategically significant for rapid-onset conditions. When a drug is inhaled, it is absorbed directly through the lungs into the bloodstream, producing a much faster therapeutic effect than swallowed tablets, which must pass through the digestive system first. For a condition like a panic attack, where timing is central to effective treatment, this pharmacological speed advantage is material.
IRX-616a is formulated using cannabidiol (CBD), a non-intoxicating compound derived from the cannabis plant. The formulation is differentiated by its inhaled delivery mechanism, designed to match the acute, episodic nature of panic attacks rather than providing background daily suppression.
IRX-616a sits within a broader three-asset pipeline, backed by a funding facility of up to $52.3 million secured to advance all three programmes:
- IRX-616a — Panic Disorder
- IRX-211 — Breakthrough Cancer Pain
- SRX-25 — Treatment-Resistant Depression
The company’s overarching regulatory strategy targets US FDA approval via the 505(b)(2) pathway, a route designed to be more cost-effective and faster than a standard new drug application by leveraging existing safety and efficacy data.
Phase 1 outcomes and what comes next for IRX-616a
Key outcomes from the Phase 1 study
The Phase 1 trial was a randomised, double-blind, placebo-controlled study conducted at CMAX Adelaide, assessing safety, tolerability, and pharmacokinetic parameters across three sequential dose cohorts in healthy volunteers. The most significant outcome from the dosing phase is the clean safety record: zero SAEs were reported across the entirety of the study.
This result carries particular weight ahead of Phase 2 advancement, as first-in-human studies carry inherent execution risk and a clean safety profile provides a stronger foundation for regulatory discussions. Management has described the pharmacokinetic data as providing “early insights,” and it is important to note that final data analysis is still underway. Database lock and final statistical analysis have now commenced.
| Study Design | Trial Site | Cohorts | Safety Outcome | Current Status |
|---|---|---|---|---|
| Randomised, double-blind, placebo-controlled | CMAX Adelaide | 3 sequential dose cohorts | 0 SAEs reported | Database lock underway |
The road to Phase 2 — next milestones
The company has outlined four confirmed next steps in sequence, drawn directly from the announcement:
- Completion of database lock and statistical analysis
- Review of final safety and pharmacokinetic data
- Release of topline Phase 1 results
- Advancement into Phase 2 clinical development in the target patient population
A key distinction in Step 4 is the move from healthy volunteers to the target patient population, people living with Panic Disorder. This is a meaningful clinical progression, as data generated in real patients carries significantly more weight for regulatory submissions than data from healthy individuals.
Importantly, Phase 2 planning and regulatory preparation activities have already been initiated, indicating no delay between phases. NX1 has confirmed it will issue further updates as material milestones are achieved.
The next major ASX story will hit our subscribers first
Investment thesis — why this milestone strengthens the NX1 case
The completion of the LPLD milestone with zero SAEs materially de-risks the IRX-616a programme. The dosing phase of a first-in-human study carries genuine execution risk, and its clean conclusion removes a significant clinical hurdle on the path to Phase 2.
From a capital perspective, the $52.3 million funding facility secured to advance all three pipeline programmes means that near-term development timelines are not constrained by capital availability. This provides a degree of visibility over the company’s ability to execute across IRX-616a, IRX-211, and SRX-25 concurrently.
The 505(b)(2) regulatory strategy is also worth noting for investors assessing time-to-market potential. This pathway allows NX1 to rely, in part, on previously established safety and efficacy data, potentially compressing both the cost and timeline of achieving FDA approval relative to a full new drug application.
The next material news event investors should monitor is the release of topline Phase 1 data, which will follow the completion of database lock and final statistical analysis. Until that data is released, the absence of SAEs represents the primary clinical signal available. Investors should note that no conclusions can yet be drawn regarding efficacy.
Don’t Miss the Next ASX Healthcare Breakthrough
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis. Over 20,000 subscribers already rely on it to stay ahead of market-moving announcements. Click the “Free Alerts” button at StockWire X to make sure the next clinical milestone lands in your inbox the moment it breaks.